✦ LIBER ✦

PREDICTION OF 5-YEAR CLINICAL OUTCOMES USING THE SYNTAX SCORE IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FROM THE SIROLIMUS-ELUTING STENT COMPARED WITH PACLITAXEL-ELUTING STENT FOR CORONARY REVASCULARIZATION (SIRTAX) TRIAL

✍ Scribed by Girasis, Chrysafios; Garg, Scot; Räber, Lorenz; Sarno, Giovanna; Morel, Marie-angèle; Garcia-Garcia, Hector; Serruys, Patrick W.; Windecker, Stephan

Book ID: 122438013
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 74 KB
Volume: 55
Category: Article
ISSN: 1558-3597
DOI: 10.1016/S0735-1097(10)61808-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Twelve-month clinical outcomes of everol

Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials

✍ Salvatore Cassese; Raffaele Piccolo; Gennaro Galasso; Roberta De Rosa; Federico 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 648 KB

The syntax score predicts freedom from e

The syntax score predicts freedom from events in patients with multivessel coronary artery disease undergoing percutaneous intervention with drug-eluting stents

✍ DH Steinberg; MA Gaglia Jr.; TL Pinto Slottow; P Roy; T Okabe; R Torguson; K Kan 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 75 KB

COST EFFECTIVENESS OF EVEROLIMUS- VS. PA

COST EFFECTIVENESS OF EVEROLIMUS- VS. PACLITAXEL-ELUTING STENTS FOR PATIENTS UNDERGOING PERCUTANEOUS CORONARY REVASCULARIZATION. 2-YEAR RESULTS FROM THE SPIRIT-IV TRIAL

✍ Amin, Amit P.; Reynolds, Matthew R.; Lei, Yang; Mahoney, Elizabeth M.; Robertus, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 118 KB

Risk of Thrombosis With the Use of Sirol

Risk of Thrombosis With the Use of Sirolimus-Eluting Stents for Percutaneous Coronary Intervention (from Registry and Clinical Trial Data)

✍ Anthony A. Bavry; Dharam J. Kumbhani; Thomas J. Helton; Deepak L. Bhatt 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 173 KB

Improved Late Clinical Safety With Zotar

Improved Late Clinical Safety With Zotarolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in Patients With De Novo Coronary Lesions: 3-Year Follow-Up From the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) Trial

✍ Martin B. Leon; Eugenia Nikolsky; Donald E. Cutlip; Laura Mauri; Henry Liberman; 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 557 KB

In-Hospital and 1-Year Outcomes Among Un

In-Hospital and 1-Year Outcomes Among Unselected Percutaneous Coronary Intervention Patients Treated With Either Sirolimus- or Paclitaxel-Eluting Stents: Results From the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) Registry

✍ Victor Novack; Donald Cutlip; Neal Kleiman; Michael Pencina; Laura Mauri; Chen-H 📂 Article 📅 2009 🏛 American College of Cardiology 🌐 English ⚖ 939 KB